Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.
2018
5549Background: Mirvetuximab soravtansine is an ADC, comprising a FRα-binding antibody linked to the tubulin-disrupting maytansinoid DM4, currently being evaluated in combination with bevacizumab a...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI